ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
- Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 PASADENA, ...
Wieme, R. J., Demeulenaere, L., and Segers, J., Prot. Biol. Fluids (Proc. Fifteenth Colloq., Bruges), 15, 499 (Elsevier, Amsterdam, 1968).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results